This trial is evaluating whether Cabozantinib will improve 1 primary outcome and 5 secondary outcomes in patients with Renal Cell Adenocarcinoma. Measurement will happen over the course of Baseline and week 12 after treatment initiation.
This trial requires 19 total participants across 1 different treatment group
This trial involves a single treatment. Cabozantinib is the primary treatment being studied. Participants will all receive the same treatment. There is no placebo group. The treatments being tested are in Phase 2 and have already been tested with other people.
"A new case of RCC will develop in 1 in 20 of those with cancer in the United States. To our knowledge, this is the first documentation of this data. Copyright © 2015 John Wiley & Sons, Ltd." - Anonymous Online Contributor
"It is important that patients with [kidney cancer](https://www.withpower.com/clinical-trials/kidney-cancer) should receive an appropriately tailored discussion about any possible signs to prompt detection and to discuss options for diagnosis. summary: This article is part of a series called "What are the signs of?" that is part of the Medline Plus database (a project of the United States National Library of Medicine). The complete series covers inflammatory, infectious, endocrine and metabolic diseases, cancers, and anatomy and embryology. For more information on this series, see http://www.medlineplus.gov." - Anonymous Online Contributor
"The vast majority of patients with renal cell carcinoma or other solid tumor are treated with some form of chemotherapy. Other treatments include surgery, external beam radiation, and photodynamic therapy." - Anonymous Online Contributor
"Carcinoma is a form of cancer that arises in cells that line or cover organs, such as skin, lungs, stomach, esophagus, pancreas, liver, urinary tract, heart, and brain. It results in unregulated growth of cancer cells that form masses. The disease can occur in adults of any age, although most cases occur in adults ages 40-80." - Anonymous Online Contributor
"The causes for the development of carcinoma, renal cell, are largely unknown. The most recent data on this disease, from the NCI database, show that in our time (from 1975 to 2000), there was a modest and steady increase in the number of patients diagnosed with carcinoma, renal cell, from 750 to 10,030 cases. This may be attributable to increased use of medical imaging. In order to properly understand the incidence and etiology of the disease, a thorough review of the entire data on the epidemiology of both renal oncology (i.e., carcinoma, renal cell) and the etiology of renal oncology is necessary." - Anonymous Online Contributor
"It seems that we can reduce the number of patients needing surgery by performing a preoperative nephrectomy. Nephrectomy for kidney carcinoma provides an opportunity to cure the tumor and can be performed in selected patients under close supervision." - Anonymous Online Contributor
"The incidence of [cancer, renal cell] is very low and most cases will have a primary tumour other than renal cell carcinoma. [Carcinoma, renal cell] presents an elderly male predominance and more importantly, a higher frequency of coexisting conditions like tobacco smoking or alcoholism; some of these conditions are common to renal cell carcinoma (carcinoma, renal cell)\n" - Anonymous Online Contributor
"Most of the common side effects seen in preclinical studies were also reported with cabozantinib. The most common side effects were fatigue, nausea, dizziness, headache, diarrhea, constipation, fever, and sweating. Cabozantinib was also associated with an increased risk of liver toxicity, including hepatic adenomas, HCC, and AML, as well as other benign neoplasms. Because hepatic function must be monitored closely during treatment for carcinoma, cabozantinib should be discontinued when these adverse events occur." - Anonymous Online Contributor
"The data from this study suggest that cabozantinib administered as a single agent had an acceptable safety profile, but did not increase progression-free survival over placebo in this pre-selected advanced renal cell carcinoma patient population. In addition to the absence of efficacy, we found significant dose reductions of cabozantinib were associated with increased grade 3 and 5 adverse events and deaths." - Anonymous Online Contributor
"Cabozantinib exerts significant effects on cell proliferation and angiogenesis in vitro. It also may have an impact on the tumor microenvironment in vitro but no evidence was found for its effects in vivo. Findings from a recent study suggest that this molecule, which acts as a tyrosine kinase inhibitor, may be a promising drug in the treatment of soft-tissue sarcomas." - Anonymous Online Contributor
"There are many different types of renal cell carcinoma, which often result in different prognoses. For patients with renal cell carcinoma over 20% with stage 2 to 4 diseases, there are two clinical trials for renal cell carcinoma. For stage 2 to 4 renal cell carcinoma, clinical trials have been conducted that focus on the drug temsirolimus in treatment options." - Anonymous Online Contributor
"Cabozantinib, which was initially developed for the treatment of kidney cancer, is in phase III clinical study for the treatment of DIPG in a large-scale, single-arm, open-label trial. Data from a recent study will be discussed in further detail in forthcoming articles." - Anonymous Online Contributor